In 2017 the Physical Activity Working Group is established, as part of the COPD Biomarker Qualification Consortium (CBQC). The Biomarkers Consortium is created to help qualify new tools to support development of better treatment and medicines that will help improve the lives of those with COPD.

The DynaPort MoveMonitor was used in a Phase IV pharmaceutical trial to search for the efficacy of a COPD drug.

The DynaPort MoveMonitor was used in a Phase IIb pharmaceutical trial to evaluate the efficacy and safety of a medication for the treatment of patients with COPD.

The main goal of E-NO FALLS thematic network is to integrate and bring together knowledge, experiences and best practices acquired at European and international level in the area of fall prevention, intervention and safety, with the aim of coordinating ongoing activities and creating the necessary conditions and consensus on action plans, standards and specifications in view to ensure the widest future replication and co-deployment of innovative solutions (with special emphasis on ICT-based ones).

PHYSACTO explored the effects of bronchodilator therapy and exercise training, when added to a behavioral modification program, on exercise capacity and physical activity levels in patients with COPD.